Epocrates Drug Updates - Editor's Pick

March 2, 2016
Otiprio Approved for Bilateral Otitis Media

The FDA recently approved Otiprio (ciprofloxacin otic) for the treatment of bilateral otitis media in pediatric patients 6 months and older undergoing tympanostomy tube placement. Otiprio has a different route from that of existing ciprofloxacin otic products; it is given intratympanically in the ear(s) as a one-time dose following suctioning of the middle ear effusion. Otiprio consists of a thermosensitive gel that is a liquid at or below room temperature and gels when warmed.
Otiprio

January 19, 2016
Genvoya Approved for HIV-1 Infection

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a new fixed-dose, once-daily complete regimen for HIV-1 infection treatment in pts 12 yrs and older. Its boxed warning states that it can cause lactic acidosis and severe hepatomegaly. Genvoya contains tenofovir alafenamide, a new prodrug that appears to be associated w/ less kidney toxicity and loss in bone density than the previously approved tenofovir disoproxil, and has a different drug interaction profile.
Genvoya

New Drug Monographs

What is an RSS Feed?

From Wikipedia: "RSS is a simple XML-based system that allows users to subscribe to their favorite websites. Using RSS, webmasters can put their content into a standardized format, which can be viewed and organized through RSS-aware software or automatically conveyed as new content on another website."

email Subscribe by email

Enter your email address:


   Cancel

Delivered by FeedBurner

Errata

January 19, 2016
The Gabitril and generic tiagabine monographs have been updated to correct the pediatric dosing for adjunct treatment of partial seizures to 32 mg/day PO divided bid-qid, up to a max dose of 32 mg/day. Please update your Epocrates app regularly to ensure that you always have the latest content.